🇺🇸 FDA
Pipeline program

Oxycyte

OX-CL-II-005

Phase 2 small_molecule terminated

Quick answer

Oxycyte for Traumatic Brain Injury is a Phase 2 program (small_molecule) at TENAX THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
TENAX THERAPEUTICS, INC.
Indication
Traumatic Brain Injury
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials